Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari’s global intellectual property...
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at...
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor...
CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND timeline...
TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing...
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating...
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating...
Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline Access the Akari CEO Corner here ...
TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology...
TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology...